A hemi‐spleen injection model of liver metastasis for prostate cancer
Abstract
Liver metastasis is not uncommon in men with metastatic castration‐resistant prostate cancer (mCRPC), estimated at ~20% to 60% of advanced late‐stage patients. Liver and other visceral metastases are associated with worse overall survival. Recent evidence suggests the frequency of visceral metastases may be increasing for reasons that are unclear but may be related to selective pressures induced by modern therapies, including second‐generation antiandrogen receptor signaling inhibitors such as enzalutamide and abiraterone. Consequently, robust models to study the pathobiology of prostate cancer liver metastases and their response to therapy are urgently needed.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 06, 2020
- Source ID
- 10.1002/pros.24055
Entities
People
- Brian W. Simons
- Lei Zheng
- Marc Rosen
- Susan Dalrymple
- W Nathaniel Brennen
Organizations
- Institut National du Cancer
- Johns Hopkins University
- United States Department of Defense